Retigabine

Seizures

GlaxoSmithKlineSmall moleculePhase 4 / ApprovedDormant

BB

67/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 52/ 100
Competitive Position: 89/ 100

Competitive context

77 Active assets in the Seizures cohort.

Asset / Sponsor	Phase	Rating
Topamax SK Life Science, Inc.	Phase 4	BBB
Keppra Beijing Tiantan Hospital	Phase 4	BBB
Carbamazepine Assistance Publique - Hôpitaux de Paris	Phase 4	BBB
LAMOTRIGINE Assiut University	Phase 4	BBB
Topamax Université de Sherbrooke	Phase 4	BBB

View all 50 →

Same molecule, other indications

Retigabine is also rated in:

epilepsyDormant

BB

Indicative ·

69 / 100

childhood-onset epilepsy syndromeDormant

CCC

Indicative ·

54 / 100

diseaseDormant

CCC

Indicative ·

54 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.